targeted therapy

Overcome drug resistance by targeting host proteins.

Streamlining drug development workflows with cell, tissue, and small animal imagers

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.

Enrolling the right patient population could be key to a successful clinical trial.